U.S. Markets open in 8 mins
  • S&P Futures

    3,634.75
    +7.50 (+0.21%)
     
  • Dow Futures

    29,884.00
    +56.00 (+0.19%)
     
  • Nasdaq Futures

    12,199.75
    +47.50 (+0.39%)
     
  • Russell 2000 Futures

    1,842.80
    -1.80 (-0.10%)
     
  • Crude Oil

    45.37
    -0.34 (-0.74%)
     
  • Gold

    1,810.70
    -0.50 (-0.03%)
     
  • Silver

    23.28
    -0.16 (-0.69%)
     
  • EUR/USD

    1.1932
    +0.0018 (+0.1551%)
     
  • 10-Yr Bond

    0.8780
    -0.0040 (-0.45%)
     
  • Vix

    21.40
    -0.24 (-1.11%)
     
  • GBP/USD

    1.3327
    -0.0030 (-0.2226%)
     
  • USD/JPY

    104.1520
    -0.0980 (-0.0940%)
     
  • BTC-USD

    17,075.21
    -91.44 (-0.53%)
     
  • CMC Crypto 200

    333.94
    -36.57 (-9.87%)
     
  • FTSE 100

    6,331.71
    -31.22 (-0.49%)
     
  • Nikkei 225

    26,644.71
    +107.40 (+0.40%)
     

Autolus Therapeutics to Participate in Upcoming Investor Conferences in September

LONDON, Aug. 28, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that management will participate in the following investor conferences in September:

  • Dr. Christian Itin, chairman and chief executive officer, will present at the Wells Fargo 2019 Healthcare Conference in Boston on Wednesday, September 4 at 3:00 p.m. ET and will host one-on-one meetings with attendees. A live webcast of the presentation will be available on the investor relations section of Autolus’ website at https://www.autolus.com. An archived replay will be available on the company’s website for a period of 90 days after the conference.

  • Dr. Itin will participate in a fireside chat at the Morgan Stanley 17th Annual Global Healthcare Conference in New York on Monday, September 9 at 9:20 a.m. ET and will host one-on-one meetings with attendees. A live audio webcast of the fireside chat will be available on the investor relations section of Autolus’ website at https://www.autolus.com. An archived replay will be available on the company’s website for a period of 90 days after the conference.

  • Andrew Oakley, chief financial officer, will present at the H.C. Wainwright 21st Annual Global Investment Conference in New York on Tuesday, September 10 at 2:10 p.m. ET and will host one-on-one meetings with attendees.

About Autolus Therapeutics plc

Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors. For more information, go to: https://www.autolus.com.

Investor contact:
Susan A. Noonan
S.A. Noonan Communications
+1-212-966-3650
susan@sanoonan.com

Media contacts:
Silvia Taylor
Vice President, Corporate Affairs and Communications
Autolus
+1-240-801-3850
s.taylor@autolus.com

Julia Wilson
JW Communications
+44 (0) 7818 430877
j.wilson@autolus.com